News headlines about BeiGene (NASDAQ:BGNE) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BeiGene earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.6549197202614 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
Shares of NASDAQ BGNE traded down $1.60 during trading on Monday, reaching $166.62. The company had a trading volume of 181,819 shares, compared to its average volume of 395,129. BeiGene has a twelve month low of $34.36 and a twelve month high of $182.79. The stock has a market cap of $9,010.70, a price-to-earnings ratio of -74.72 and a beta of 0.22. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23.
BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The firm had revenue of $18.17 million during the quarter, compared to the consensus estimate of $23.00 million. analysts anticipate that BeiGene will post -7.69 EPS for the current year.
A number of analysts have commented on the company. Maxim Group set a $200.00 target price on BeiGene and gave the stock a “buy” rating in a research report on Monday. ValuEngine upgraded BeiGene from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Piper Jaffray assumed coverage on BeiGene in a research report on Friday. They set an “overweight” rating and a $200.00 target price on the stock. BidaskClub upgraded BeiGene from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Finally, Zacks Investment Research upgraded BeiGene from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $158.71.
In related news, Director Bros. Advisors Lp Baker purchased 1,980,198 shares of the business’s stock in a transaction dated Thursday, January 18th. The stock was bought at an average cost of $101.00 per share, with a total value of $199,999,998.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Howard Liang sold 40,000 shares of the company’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $160.27, for a total value of $6,410,800.00. Following the completion of the transaction, the chief financial officer now owns 15,872 shares of the company’s stock, valued at $2,543,805.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 194,210 shares of company stock valued at $29,041,676. Insiders own 19.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/16/beigene-bgne-earns-daily-coverage-optimism-score-of-0-20.html.
BeiGene Company Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.